Yeah, I mean, if you were a large pharmaceutical with a weak pipeline, do the math. Look at the top-line of Gleevec, alone. I know I'm "talking my own book" here, but, I jsut don't see a better small-cap biotechnology play right now. If, within the next 9 months, you start seeing NSCLC patients with ALK resistant mutations being "cured" the way Ponatinib handled the T315i mutation, its really going to add gasoline to this pig. "Pig roast". And, it will be an open-label study, so, it shouldn't be too hard to see whether or not its working.
